Short Interest in Femasys Inc. (NASDAQ:FEMY) Grows By 70.1%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 3,326,404 shares, an increase of 70.1% from the May 14th total of 1,955,435 shares. Based on an average trading volume of 3,901,852 shares, the days-to-cover ratio is currently 0.9 days. Approximately 6.0% of the company’s shares are sold short.

Femasys Trading Down 4.8%

Shares of NASDAQ:FEMY traded down $0.20 during trading on Monday, reaching $3.98. The stock had a trading volume of 97,246 shares, compared to its average volume of 49,786. The firm’s fifty day moving average is $7.61 and its 200 day moving average is $10.90. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91. Femasys has a 52 week low of $3.87 and a 52 week high of $22.20. The stock has a market cap of $12.02 million, a price-to-earnings ratio of -0.74 and a beta of -2.23.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Friday, May 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $1.43. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%. The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.77 million.

Analyst Ratings Changes

FEMY has been the topic of a number of analyst reports. Lake Street Capital initiated coverage on shares of Femasys in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $30.00 price objective on the stock. Wall Street Zen raised shares of Femasys to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Femasys currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Femasys by 50.8% during the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after acquiring an additional 131,052 shares during the period. Banco BTG Pactual S.A. acquired a new position in shares of Femasys during the 4th quarter valued at $88,000. Jane Street Group LLC acquired a new position in shares of Femasys during the 2nd quarter valued at $82,000. State Street Corp lifted its position in shares of Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the period. Finally, Osaic Holdings Inc. acquired a new position in shares of Femasys during the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.